AML | Clinical

FDA Lifts Partial Clinical from Study of RVU120 in Relapsed/Refractory AML and MDS

July 15, 2021

The FDA has lifted its partial clinical hold on a phase 1B study of RVU120, which is an investigation of the agent for the treatment of patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome.

Remissions in Newly Diagnosed, High-Risk/Secondary AML Appear Deeper With CPX-351

May 25, 2021

Deeper remissions in patients with newly diagnosed, high-risk/secondary acute myeloid leukemia may be achieved with CPX-351 treatment and lead to improvement in overall survival, according to post hoc analyses of a phase 3 study.

SNDX-5613 Demonstrates Robust Clinical Activity in MLL-Rearranged and NPM1c-Mutant R/R Acute Leukemia

April 21, 2021

In the phase 1/2 AUGMENT-101 clinical trial, treatment with the novel menin-MLL small molecule inhibitor SNDX-5613 led to robust clinical responses in patients with mixed lineage leukemia rearranged and NPM1c-mutant relapsed or refractory acute leukemias.